Shanghai Aladdin Biochemical Technology Co. Ltd. Class A

As of June 30, 2026, Shanghai Aladdin Biochemical Technology Co. Ltd. Class A carries a market capitalization of 10.03B, placing it among publicly traded companies globally. Its enterprise value stands at 9.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shanghai Aladdin Biochemical Technology Co. Ltd. Class A's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Shanghai Aladdin Biochemical Technology Co. Ltd. Class A has 362.01M shares outstanding.

As of June 30, 2026, Shanghai Aladdin Biochemical Technology Co. Ltd. Class A trades at a trailing price-to-earnings ratio of 79.15. The price-to-sales ratio is 12.01, and the price-to-book ratio stands at 7.44.

As of June 30, 2026, Shanghai Aladdin Biochemical Technology Co. Ltd. Class A trades at an EV/EBITDA multiple of 59.49 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 12.99 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 59.49 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 9.98B versus a market cap of 10.03B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Shanghai Aladdin Biochemical Technology Co. Ltd. Class A maintains a current ratio of 2.03, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Shanghai Aladdin Biochemical Technology Co. Ltd. Class A posted a return on equity (ROE) of 9.63, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.33 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.22, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.55, useful for judging operating efficiency across full business cycles. The company generates approximately 895,585.81 in revenue per employee across its workforce of 857.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.49 indicates how many times Shanghai Aladdin Biochemical Technology Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Shanghai Aladdin Biochemical Technology Co. Ltd. Class A recorded 16.48M in income tax expense. That works out to an effective tax rate of 9.86, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 167.19M, leaving 116.49M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Shanghai Aladdin Biochemical Technology Co. Ltd. Class A's stock has gained approximately 33.33% over the past 52 weeks. The 50-day moving average sits at 20.29, while the 200-day moving average is 19.34.

Over the twelve months ended June 30, 2026, Shanghai Aladdin Biochemical Technology Co. Ltd. Class A generated 767.96M in revenue and converted that into 116.49M in net income, yielding earnings per share of 0.44. EBITDA reached 167.71M, while operating income came in at 205.17M.

As of June 30, 2026, Shanghai Aladdin Biochemical Technology Co. Ltd. Class A holds 719.66M in cash and equivalents against 458.64M in total debt, resulting in a net debt position of -119.74M. Total book value stands at 1.35B, with working capital of 798.19M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai Aladdin Biochemical Technology Co. Ltd. Class A posted a gross margin of 64.54, reflecting its pricing power and cost economics. The operating margin of 26.72 and net profit margin of 15.17 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Shanghai Aladdin Biochemical Technology Co. Ltd. Class A paid dividends of 0.29 per share. The dividend payout ratio of 52.65 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.08, meaning Shanghai Aladdin Biochemical Technology Co. Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shanghai Aladdin Biochemical Technology Co. Ltd. Class A's most recent stock split took place on June 5, 2025 with a 5:6 split ratio.

As of June 30, 2026, Shanghai Aladdin Biochemical Technology Co. Ltd. Class A has an Altman Z-Score of 6.81, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.